Connect
MJA
MJA

Migraine: a brain state amenable to therapy

Michael Eller and Peter J Goadsby
Med J Aust 2020; 212 (1): . || doi: 10.5694/mja2.50435
Published online: 13 January 2020

Summary

  • Migraine affects over a billion people worldwide in any year and is the second most common cause of years lost due to disability. Not “just a headache”, morbidity washes though society and carries a substantial economic and social cost.
  • Understanding of migraine pathophysiology has progressed significantly. Animal models and functional neuroimaging have yielded significant insight into brain structures that mediate migraine symptoms. The role of small peptides as neurotransmitters within this network has been elucidated, allowing the generation of novel therapeutic approaches that have been validated by randomised placebo‐controlled trials.
  • Migraine is underdiagnosed and undertreated. Treatment of migraine should be proactive. An acute and, when indicated, preventive strategy should be formulated with the patient. Comorbid medication overuse must be supportively managed.
  • Migraine‐specific medications are making their way from bench to bedside. They promise an improved safety profile and ease of use in comparison to older, repurposed medications. Devices promise a non‐drug alternative should patients prefer. The migraine understanding and treatment landscape is changing rapidly.

  • 1 Monash Medical Centre, Melbourne, VIC
  • 2 UCSF Headache Center, San Francisco, CA, USA


Correspondence: peter.goadsby@ucsf.edu

Competing interests:

No relevant disclosures.

  • 1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–1259.
  • 2. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol 2016; 16: 76–87.
  • 3. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343–349.
  • 4. Buse DC, Pearlman SH, Reed ML, et al. Opioid use and dependence among persons with migraine: results of the AMPP Study. Headache 2012; 52: 18–36.
  • 5. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2011; 19: 703–711.
  • 6. Goadsby PJ, Holland PR, Martins‐Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 2017; 97: 553–622.
  • 7. Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin‐triggered migraine attacks. Brain 2014; 137: 232–241.
  • 8. Amin FM, Asghar MS, Houggard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross‐sectional study. Lancet Neurol 2013; 12: 454–461.
  • 9. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1–211.
  • 10. Brennan KC, Bates EA, Shapiro RE, et al. Casein kinase iδ mutations in familial migraine and advanced sleep phase. Sci Transl Med 2013; 5: 183ra56.
  • 11. de Vries B, Anttila V, Freilinger T, et al. Systematic re‐evaluation of genes from candidate gene association studies in migraine using a large genome‐wide association data set. Cephalalgia 2016; 36: 604–614.
  • 12. Shurks M, Rist P, Bigal M, et al. Migraine and cardiovascular disease: systematic review and meta‐analysis. BMJ 2009; 339: b3914.
  • 13. Adelborg K, Szeplegeti S, Holland‐Bill L, et al. Migraine and the risk of cardiovascular diseases: Danish population based matched cohort study. BMJ 2018; 360: k96.
  • 14. Riesco N, Pérez‐Alvarez AI, Verano L, et al. Prevalence of cranial autonomic parasympathetic symptoms in chronic migraine: usefulness of a new scale. Cephalalgia 2015; 36: 346–350.
  • 15. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19: 115–127.
  • 16. Eross E, Dodick D, Eross M. The Sinus, Allergy and Migraine Study (SAMS). Headache 2007; 47: 213–224.
  • 17. Quintela E, Castillo J, Munoz P, Pascual J. Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia 2006; 26: 1051–1060.
  • 18. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003; 60: 935–940.
  • 19. Giffin NJ, Lipton RB, Silberstein SD, et al. The migraine postdrome. Neurology 2016; 87: 309–313.
  • 20. Tepper SJ, Dahlöf CGH, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004; 44: 856–864.
  • 21. Lipton RB, Dodick D, Sadovsky R, et al. A self‐administered screener for migraine in primary care: the ID Migraine validation study. Neurology 2003; 61: 375–382.
  • 22. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008; 71: 1821–1828.
  • 23. Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010; 81: 428–432.
  • 24. Eller M, Goadsby P. MRI in headache. Expert Rev Neurother 2013; 13: 263–273.
  • 25. Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short‐term prevention of menstrually related migraine: data from two randomized, double‐blind, placebo‐controlled studies. Headache 2007; 47: 1037–1049.
  • 26. Eller M, Gelfand AA, Riggins NY, et al. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. Neurology 2016; 86: 856–859.
  • 27. Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003; 23: 963–971.
  • 28. Charles A. Migraine. N Engl J Med 2017; 377: 553–561.
  • 29. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 2010; 9: 285–298.
  • 30. Schoenen J, Coppola G. Efficacy and mode of action of external trigeminal neurostimulation in migraine. Expert Rev Neurotherapeutics 2018; 18: 545–555.
  • 31. Chou DE, Gross GJ, Casadei CH, Yugrakh MS. External trigeminal nerve stimulation for the acute treatment of migraine: open‐label trial on safety and efficacy. Neuromodulation 2017; 20: 678–683.
  • 32. Goadsby PJ, Lipton RB, Ferrari MD. Migraine — current understanding and treatment. N Engl J Med 2002; 346: 257–270.
  • 33. Diener H‐C, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double‐blind, placebo‐controlled study. Cephalalgia 2007; 27: 814–823.
  • 34. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017; 377: 2123–2132.
  • 35. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurol 2017; 16: 425–434.
  • 36. Turner DP, Golding AN, Houle TT. Using a graphical risk tool to examine willingness to take migraine prophylactic medications. Pain 2016; 157: 2226–2234.
  • 37. Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 2016; 37: 470–485.
  • 38. Jackson JL, Cogbill E, Santana‐Davila R, et al. A comparative effectiveness meta‐analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10: e0130733.
  • 39. Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple‐blind, placebo‐controlled, double cross‐over study. Cephalalgia 2013; 34: 523–532.
  • 40. Diener H‐C, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009; 29: 1021–1027.
  • 41. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; (6): CD010611.
  • 42. Karsan N, Palethorpe D, Rattanawong W, et al. Flunarizine in migraine‐related headache prevention: results from 200 patients treated in the UK. Eur J Neurol 2018; 25: 811–817.
  • 43. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high‐dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 1998; 50: 466–470.
  • 44. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double‐blind, randomized, placebo‐controlled phases of the PREEMPT Clinical Program. Headache 2010; 50: 921–936.
  • 45. Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double‐blind, placebo‐controlled study. Cephalalgia 2018; 38: 1611–1621.
  • 46. Reuter U, Goadsby PJ, Lanteri‐Minet M, et al. Efficacy and tolerability of erenumab in episodic migraine patients who previously failed 2–4 preventive treatments: a randomised placebo‐controlled phase 3b study. Lancet 2018; 392: 2280–2287.
  • 47. Schoenen JE. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2016; 86: 201–202.
  • 48. Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study. Neurology 2016; 87: 529–538.
  • 49. Blumenfeld AM, Stark RJ, Freeman MC, et al. Long‐term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018; 19: 13.
  • 50. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 54–61.
  • 51. Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia 2017; 39: 366–373.
  • 52. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48–56.
  • 53. Russell FA, King R, Smillie SJ, et al. Calcitonin gene‐related peptide: physiology and pathophysiology. Physiol Rev 2014; 94: 1099–1142.
  • 54. Walker CS, Eftekhari S, Bower RL, et al. A second trigeminal CGRP receptor: function and expression of the AMY 1receptor. Ann Clin Transl Neurol 2015; 2: 595–608.
  • 55. Goadsby PJ. Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients. Brain 2016; 139: 2571–2577.
  • 56. Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2017; 38: 1038–1048.
  • 57. Bhola R, Kinsella E, Giffin N, et al. Single‐pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain 2015; 16: 535.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Changing practice: incidence of non‐reconstructive arthroscopic knee surgery in people over 50 years of age, Australia, 2008–2018

So Mang (Simon) Lee, Wasim Awal and Christopher Vertullo
Med J Aust 2020; 212 (1): . || doi: 10.5694/mja2.50436
Published online: 13 January 2020

The results of low bias randomised controlled trials over the past 6 years have suggested that the outcomes of arthroscopic partial meniscectomies in people with non‐obstructive degenerative medial meniscal tears are similar to those of sham surgery1 or structured rehabilitation.2 Further, older randomised trials found that arthroscopic lavage and debridement is no more beneficial for patients with uncomplicated osteoarthritis than placebo treatments.3 As this evidence cast doubts upon the efficacy of arthroscopic meniscectomy for degenerative meniscal pathology, we investigated the 10‐year incidence of non‐reconstructive, non‐reparative arthroscopic knee procedures in Australia in people over 50 years of age.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 Griffith University, Gold Coast, QLD
  • 2 Knee Research Australia, Gold Coast, QLD
  • 3 Gold Coast Orthopaedic Research and Education Alliance, Griffith University, Gold Coast, QLD



Competing interests:

No relevant disclosures.

  • 1. Sihvonen R, Paavola M, Malmivaara A, et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med 2013; 369: 2515–2524.
  • 2. Kise NJ, Risberg MA, Stensrud S, et al. Exercise therapy versus arthroscopic partial meniscectomy for degenerative meniscal tear in middle aged patients: randomised controlled trial with two year follow‐up. BMJ 2016; 354: i3740.
  • 3. Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347: 81–88.
  • 4. Australian Institute of Health and Welfare. Procedures data cubes, 2008–09 to 2017–18. Updated May 2019. https://www.aihw.gov.au/reports/hospitals/procedures-data-cubes/contents/data-cubes (viewed Oct 2019).
  • 5. Harris IA, Madan NS, Naylor JM, et al. Trends in knee arthroscopy and subsequent arthroplasty in an Australian population: a retrospective cohort study. BMC Musculoskelet Disord 2013; 14: 143.
  • 6. Feeley B, Liu S, Garner AM, et al. The cost‐effectiveness of meniscal repair versus partial meniscectomy: a model‐based projection for the United States. Knee 2016; 23: 674–680.
  • 7. Barlow T, Plant CE. Why we still perform arthroscopy in knee osteoarthritis: a multi‐methods study. BMC Musculoskelet Disord 2015; 16: 85.
  • 8. The Royal Australian College of General Practitioners. Guidelines for management of knee and hip osteoarthritis Second edition. Melbourne: RACGP, 2018. https://www.racgp.org.au/download/Documents/Guidelines/Musculoskeletal/guideline-for-the-management-of-knee-and-hip-oa-2nd-edition.pdf (viewed Oct 2019).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Prospective data confirm the lasting effects of maltreatment on children

Steve Kisely and Jake Najman
Med J Aust 2020; 212 (1): . || doi: 10.5694/mja2.50445
Published online: 13 January 2020

Child protection services in Australia require fundamental workforce and organisational reform

The numbers of recorded cases of child maltreatment in Australia have risen sharply in recent years, accompanied by a substantial increase in the number of children placed in out‐of‐home care.1 The article by Green and colleagues2 in this issue of the MJA reports a linkage study of prospectively recorded contacts of children with child protection services during early childhood and subsequent mental health service visits between 6 and 13 years of age, based on administrative data for a representative population sample of 74 500 New South Wales children commencing school in 2009.3


  • University of Queensland, Brisbane, QLD


Correspondence: s.kisely@uq.edu.au

Competing interests:

Jake Najman has received grants from the Australian Research Council and the National Health and Medical Research Council for a longstanding birth cohort study on which some of this editorial is based.

  • 1. Australian Institute of Health and Welfare. Child protection Australia 2010–11 (Cat No. CWS 41; Child Welfare Series No. 52). Canberra: AIHW, 2012.
  • 2. Green MJ, Hindmarsh G, Kariuki M, et al. Mental disorders in children known to child protection services during early childhood. Med J Aust 2020; 212: 22–28.
  • 3. Carr VJ, Harris F, Raudino A, et al. New South Wales Child Development Study (NSW‐CDS): an Australian multiagency, multigenerational, longitudinal record linkage study. BMJ Open 2016; 6: e009023.
  • 4. Coles J, Lee A, Taft A, et al. Childhood sexual abuse and its associations with adult physical and mental health: results from a national cohort of young Australian women. J Interpers Violence 2015; 30: 1929–1244.
  • 5. Kisely S, Abajobir AA, Mills R, et al. Child maltreatment and mental health problems in adulthood: birth cohort study. Br J Psychiatry 2018; 213: 698–703.
  • 6. Scott KM, Smith DR, Ellis PM. Prospectively ascertained child maltreatment and its association with DSM‐IV mental disorders in young adults. Arch Gen Psychiatry 2010; 67: 712–719.
  • 7. Abajobir AA, Kisely S, Williams G, et al. Risky sexual behaviors and pregnancy outcomes in young adulthood following substantiated childhood maltreatment: findings from a prospective birth cohort study. J Sex Res 2018; 55: 106–119.
  • 8. Mills R, Kisely S, Alati R, et al. Child maltreatment and cannabis use in young adulthood: a birth cohort study. Addiction 2017; 112: 494–501.
  • 9. Abajobir AA, Kisely S, Williams G, et al. The association between substantiated childhood maltreatment, asthma and lung function: a prospective investigation. J Psychosom Res 2017; 101: 58–65.
  • 10. Abajobir AA, Kisely S, Williams G, et al. Height deficit in early adulthood following substantiated childhood maltreatment: a birth cohort study. Child Abuse Negl 2017; 64: 71–78.
  • 11. Lonne B, Harries M, Lantz S. Workforce development: a pathway to reforming child protection systems in Australia. Brit J Soc Work 2013; 43: 1630–1648.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Estimating the lifetime risks of cancer: the best measure depends on your purpose

Elizabeth Buckley and David M Roder
Med J Aust 2020; 212 (1): . || doi: 10.5694/mja2.50444
Published online: 13 January 2020

Estimates adjusted for competing risks of mortality can be more meaningful, but make some comparisons more difficult

The Australian Institute of Health and Welfare began collecting cancer incidence statistics at the population level during the mid‐1980s, based on state and territory registry data that are now collated by the Australian Cancer Database, supplemented by mortality data from the Australian Bureau of Statistics.1 These data inform Australian policy makers, researchers, and the general public about cancer profiles and trends.1


  • Cancer Research Institute, University of South Australia, Adelaide, SA


Correspondence: david.roder@unisa.edu.au

Acknowledgements: 

This editorial was prepared with the financial support of the Cancer Council SA Beat Cancer Project on behalf of its donors and SA Health.

Competing interests:

David Roder receives funding from the Cancer Council SA Beat Cancer Project for his position as Cancer Research Chair at the University of South Australia.

  • 1. Jelfs P, Coates M, Giles G, et al. Cancer in Australia 1989–1990 (with projections to 1995) (AIHW 32). Canberra: Australian Institute of Health and Welfare, 1996.
  • 2. Australian Institute of Health and Welfare. Australian Cancer Database, 2014; quality statement. Dec 2017. https://meteor.aihw.gov.au/content/index.phtml/itemId/687104 (viewed Oct 2019).
  • 3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
  • 4. Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: irrelevance or ignorance? Stat Med 2012; 31: 1089–1097.
  • 5. Bach AC, Lo KSE, Pathirana T, et al. Is the risk of cancer in Australia overstated? The importance of competing mortality for estimating lifetime risk. Med J Aust 2020; 212: 17–22.
  • 6. Sasieni PD, Shelton J, Ormiston‐Smith N, et al. What is the lifetime risk of developing cancer?: the effect of adjusting for multiple primaries. Br J Cancer 2011; 105: 460–465.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Addressing inequity in acute stroke care requires attention to each component of regional workflow

Tayler Watson, Jeigh Tiu and Ben Clissold
Med J Aust 2020; 212 (1): . || doi: 10.5694/mja2.50440
Published online: 13 January 2020

A multifaceted approach will enable equitable stroke care for regional communities

About 56 000 strokes occur in Australia annually1 at an estimated economic cost of $5 billion per year.2 Inequity continues to separate regional and metropolitan populations with respect to incidence and management of acute ischaemic stroke. Risk factors for acute ischaemic stroke disproportionately burden regional Australia and this is reflected in the high rate of strokes in regional compared with metropolitan areas (250 v 210 per 100 000 population per year respectively).1 Of the 12 electorates with highest stroke incidence nationally, nine are in regional areas.1


  • 1 Monash Health, Melbourne, VIC
  • 2 Goulburn Valley Base Hospital, Shepparton, VIC
  • 3 Barwon Health, Geelong, VIC



Competing interests:

No relevant disclosures.

  • 1. Deloitte Access Economics. No postcode untouched report: stroke in Australia 2017. Melbourne: National Stroke Foundation, 2017. https://strokefoundation.org.au/What-we-do/Research/No-postcode-untouched (viewed Nov 2019).
  • 2. Deloitte Access Economics. The economic impact of stroke in Australia: Scoping cost effective prevention. Melbourne: National Stroke Foundation, 2013. https://www2.deloitte.com/au/en/pages/economics/articles/economic-impact-stroke-australia.html (viewed Nov 2019).
  • 3. National Stroke Foundation. National stroke audit: acute services report. Melbourne: National Stroke Foundation, 2017. https://informme.org.au/-/media/7D1480925C2046BA914F3F66D392B83A.ashx?la (viewed Nov 2019).
  • 4. Bray JE, Johnson R, Trobbiani K, et al. Australian public's awareness of stroke warning signs improves after national multimedia campaigns. Stroke 2013; 44: 3540–3543.
  • 5. Ambulance Victoria. Ambulance Victoria performance — 2017/18 quarter 4. Melbourne: Ambulance Victoria, 2018. https://www.ambulance.vic.gov.au/wp-content/uploads/2018/07/2017-18-Q4-Ambulance-Response-Quarter-4-FY2017-18.pdf (viewed Nov 2019).
  • 6. Walter S, Zhao H, Easton D, et al. Air‐Mobile Stroke Unit for access to stroke treatment in rural regions. Int J Stroke 2018; 13: 568–575.
  • 7. Leyden JM, Chong WK, Kleinig T, et al. A population‐based study of thrombolysis for acute stroke in South Australia. Med J Aust 2011; 194: 111–115. https://www.mja.com.au/journal/2011/194/3/population-based-study-thrombolysis-acute-stroke-south-australia
  • 8. Regenhardt RW, Mecca AP, Flavin SA, et al. Delays in the air or ground transfer of patients for endovascular thrombectomy. Stroke 2018; 49: 1419–1425.
  • 9. Silbergleit R, Scott PA, Lowell MJ, Silbergleit R. Cost‐effectiveness of helicopter transport of stroke patients for thrombolysis. Acad Emerg Med 2003; 10: 966–972.
  • 10. O'Brien W, Crimmins D, Donaldson W, et al. FASTER (Face, Arm, Speech, Time, Emergency Response): experience of Central Coast Stroke Services implementation of a pre‐hospital notification system for expedient management of acute stroke. J Clin Neurosci 2012; 19: 241–245.
  • 11. Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology 2013; 81: 1071–1076.
  • 12. Wardlaw JM, Seymour J, Cairns J, et al. Immediate computed tomography scanning of acute stroke is cost‐effective and improves quality of life. Stroke 2004; 35: 2477–2483.
  • 13. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2014; (7): CD000213.
  • 14. Kepplinger J, Barlinn K, Deckert S, et al. Safety and efficacy of thrombolysis in telestroke: a systematic review and meta‐analysis. Neurology 2016; 87: 1344–1351.
  • 15. Switzer J, Demaerschalk B, Xie J, Fan L, Villa K, Wu E. Cost‐effectiveness of hub‐and‐spoke telestroke networks for the management of acute ischemic stroke (P05.243). Neurology 2012; 78(Suppl): P05.243.
  • 16. Bagot KL, Bladin CF, Vu M, et al. Exploring the benefits of a stroke telemedicine programme: an organisational and societal perspective. J Telemed Telecare 2016; 22: 489–494.
  • 17. Moffatt JJ, Eley DS. The reported benefits of telehealth for rural Australians. Aust Health Rev 2010; 34: 276–281.
  • 18. Australian Institute of Health and Welfare. Australia's health 2016 [Australia's health series No. 15; Cat. No. AUS 199]. Canberra: AIHW, 2016. https://www.aihw.gov.au/getmedia/9844cefb-7745-4dd8-9ee2-f4d1c3d6a727/19787-AH16.pdf.aspx (viewed Nov 2019).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Symbolic sexism: superficial or serious bias? An investigation into images on patient call bells

Laura RE Chapman, Sara Mellow and Hannah Coombridge
Med J Aust 2019; 211 (11): . || doi: 10.5694/mja2.50418
Published online: 9 December 2019

Abstract

Objectives: To determine whether gendered symbols on patient call bells are restricted to our hospital or are examples of an international practice that perpetuates gender stereotypes and occupational segregation.

Setting: Multicentre, international study of hospital equipment, 2018.

Main outcome measure: Types of symbols on patient call bells.

Results: We received 56 responses from 43 hospitals in eight countries across five continents: 37 devices included female‐specific images, nine included gender‐neutral images, and ten did not use imagery (for example, button‐only devices). No call bells included male‐specific images.

Conclusion: Female symbols on patient call bells are an international phenomenon. Only female or gender‐neutral images are used, indicating bias in their design, manufacture, and selection. Female symbols may reinforce gender stereotypes and contribute to occupational segregation and reduced equity of opportunity. We suggest alternative symbols. Individual action with coloured marker pens may provide a pragmatic short term, albeit provocative, solution. While call bell design has only a minor impact on patients, everyday bias affects all staff and society in general.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 University of Auckland, Auckland, New Zealand
  • 2 Waitematā District Health Board, Auckland, New Zealand


Correspondence: l.chapman@auckland.ac.nz

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Predictors of ManuScript Rejection sYndrome (MiSeRY): a cohort study

Hui‐Chen Han, Anoop Ninan Koshy, Tina Lin, Matias Yudi, David Clark, Andrew W Teh and Omar Farouque
Med J Aust 2019; 211 (11): . || doi: 10.5694/mja2.50414
Published online: 9 December 2019

Abstract

Objectives: To assess whether specific factors predict the development of ManuScript Rejection sYndrome (MiSeRY) in academic physicians.

Design: Prospective pilot study; participants self‐administered a questionnaire about full manuscript submissions (as first or senior author) rejected at least once during the past 5 years.

Setting: Single centre (tertiary institution).

Participants: Eight academic physician‐authors.

Main outcome measures: Duration of grief. MiSeRY was pre‐specified as prolonged grief (grief duration longer than the population median).

Results: Eight participants provided data on 32 manuscripts with a total of 93 rejections (median, two rejections per manuscript; interquartile range [IQR], 1–3 rejections per manuscript). Median age at rejection was 37 years (IQR, 33–45 years); 86% of 80 rejections involved male authors (86%), 56 of the authors providing data about these rejections were first authors (60%). The median journal impact factor was 5.9 (IQR, 5.2–17). In 48 cases of rejection (52%), pre‐submission expectations of success had been high, and in 54 cases (58%) the manuscripts had been sent for external review. Median grief duration was 3 hours (IQR, 1–24 h). Multivariate analysis indicated that higher pre‐submission expectation (adjusted odds ratio [aOR], 5.0; 95% CI, 1.5–18), first author status (aOR, 9.5; 95% CI, 1.1–77), and external review (aOR, 19.0; 95% CI 2.9–126) were independent predictors of MiSeRY.

Conclusions: To help put authors out of their MiSeRY, journal editors could be more selective in the manuscripts they send for external review. Tempering pre‐submission expectations and mastering the Coping and reLaxing Mechanisms (CaLM) of senior colleagues are important considerations for junior researchers.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 Austin Health, Melbourne, VIC
  • 2 Eastern Health, Melbourne, VIC


Correspondence: huichenhan@gmail.com

Acknowledgements: 

We acknowledge the various medical journals that have rejected our manuscripts and provided inspiration for this study. To quote a contemporary poet: “thank u, next”.

Competing interests:

All but one of the rejected authors in this study are co‐authors of this article. We are uncertain whether referencing Tinder or quoting Ariana Grande infringes any copyright laws. We have no other relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

The MJA in 2019: going from very good to great!

Nicholas J Talley AC
Med J Aust 2019; 211 (11): . || doi: 10.5694/mja2.50413
Published online: 9 December 2019

We celebrate another exciting year and wish our readers a restful break and a prosperous 2020

Welcome to our 2019 Christmas issue, in which we celebrate the MJA year in review together with the traditional holiday season Down Under. As many of our readers and authors across Australia commence their well deserved breaks, we hope this more light‐hearted issue of the MJA will still inform, inspire — and amuse.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • Editor-in-Chief, the Medical Journal of Australia, on behalf of the MJA Editorial team


Correspondence: ntalley@mja.com.au

Acknowledgements: 

I would like to thank the tireless efforts of the Editorial team throughout 2019, without which the quality and timely publication of our Journal in print and online would not be possible: our Head of Publishing Content, Lilia Kanna; Senior Deputy Medical Editor, Christine Gee; Deputy Medical Editors, Francis Geronimo, Robyn Godding, Tania Janusic, Selina Lo, Wendy Morgan, and Zoë Silverstone; our Structural and Scientific Editors, Graeme Prince, Paul Foley, and Laura Teruel; our Consultant Biostatistician, Elmer Villanueva; our News and Online Editor, Cate Swannell; our Graphic Designer, Leilani Widya; and our Senior Publishing Coordinator, Kerrie Harding.

Competing interests:

No relevant disclosures for this article. A complete list of my conflict of interest disclosures is found at https://www.mja.com.au/journal/staff/

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand

Angela L Chiew, David Reith, Adam Pomerleau, Anselm Wong, Katherine Z Isoardi, Jessamine Soderstrom and Nicholas A Buckley
Med J Aust 2020; 212 (4): . || doi: 10.5694/mja2.50428
Published online: 2 December 2019

Abstract

Introduction: Paracetamol is a common agent taken in deliberate self‐poisoning and in accidental overdose in adults and children. Paracetamol poisoning is the commonest cause of severe acute liver injury. Since the publication of the previous guidelines in 2015, several studies have changed practice. A working group of experts in the area, with representation from all Poisons Information Centres of Australia and New Zealand, were brought together to produce an updated evidence‐based guidance.

Main recommendations (unchanged from previous guidelines):

  • The optimal management of most patients with paracetamol overdose is usually straightforward. Patients who present early should be given activated charcoal. Patients at risk of hepatotoxicity should receive intravenous acetylcysteine.
  • The paracetamol nomogram is used to assess the need for treatment in acute immediate release paracetamol ingestions with a known time of ingestion.
  • Cases that require different management include modified release paracetamol overdoses, large or massive overdoses, accidental liquid ingestion in children, and repeated supratherapeutic ingestions.

 

Major changes in management in the guidelines:

  • The new guidelines recommend a two‐bag acetylcysteine infusion regimen (200 mg/kg over 4 h, then 100 mg/kg over 16 h). This has similar efficacy but significantly reduced adverse reactions compared with the previous three‐bag regimen.
  • Massive paracetamol overdoses that result in high paracetamol concentrations more than double the nomogram line should be managed with an increased dose of acetylcysteine.
  • All potentially toxic modified release paracetamol ingestions (≥ 10 g or ≥ 200 mg/kg, whichever is less) should receive a full course of acetylcysteine. Patients ingesting ≥ 30 g or ≥ 500 mg/kg should receive increased doses of acetylcysteine.

 


  • 1 Prince of Wales Hospital and Community Health Services, Sydney, NSW
  • 2 NSW Poisons Information Centre, Children's Hospital at Westmead, Sydney, NSW
  • 3 University of Otago, Dunedin, New Zealand
  • 4 Victorian Poisons Information Centre, Austin Hospital, Melbourne, VIC
  • 5 Monash Health, Monash University, Melbourne, VIC
  • 6 Princess Alexandra Hospital, Brisbane, QLD
  • 7 Queensland Poisons Information Centre, Queensland Children's Hospital, Brisbane, QLD
  • 8 Royal Perth Hospital, Perth, WA
  • 9 Western Australia Poisons Information Centre, Sir Charles Gairdner Hospital, Perth, WA
  • 10 University of Sydney, Sydney, NSW



Acknowledgements: 

Angela Chiew receives funding from a National Health and Medical Research Council Early Career Fellowship (ID 1159907).

Competing interests:

Angela Chiew, Katherine Isoardi, Jessamine Soderstrom and Nicholas Buckley were involved in the 2019 Australian Therapeutic Guidelines — Toxicology and Toxinology Guidelines Writing Group and received travel and meeting expenses. Jessamine Soderstrom receives royalties from the Toxicology handbook from Elselvier. David Reith chairs the Medicines Adverse Reactions Committee for Medsafe.

  • 1. Fontana RJ. Acute liver failure including acetaminophen overdose. Med Clin North Am 2008; 92: 761–794.
  • 2. Lancaster EM, Hiatt JR, Zarrinpar A. Acetaminophen hepatotoxicity: an updated review. Arch Toxicol 2015; 89: 193–199.
  • 3. Huynh A, Cairns R, Brown JA, et al. Patterns of poisoning exposure at different ages: the 2015 annual report of the Australian Poisons Information Centres. Med J Aust 2018; 209: 74–79. https://www.mja.com.au/journal/2018/209/2/patterns-poisoning-exposure-different-ages-2015-annual-report-australian-poisons.
  • 4. eTG complete. Paracetamol poisoning [website]. Melbourne: Therapeutic Guidelines. https://www.tg.org.au. In press.
  • 5. Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and duration: past, present and future. Clin Toxicol (Phila) 2012; 50: 91–98.
  • 6. Chiew AL, Isbister GK, Duffull SB, Buckley NA. Evidence for the changing regimens of acetylcysteine. Br J Clin Pharmacol 2016; 81: 471–481.
  • 7. Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2018; (2): CD003328.
  • 8. Wong A, Graudins A. Simplification of the standard three‐bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions. Clin Toxicol (Phila) 2016; 54: 115–119.
  • 9. McNulty R, Lim JME, Chandru P, Gunja N. Fewer adverse effects with a modified two‐bag acetylcysteine protocol in paracetamol overdose. Clin Toxicol (Phila) 2018; 56: 618–621.
  • 10. Schmidt LE, Rasmussen DN, Petersen TS, et al. Fewer adverse effects associated with a modified two‐bag intravenous acetylcysteine protocol compared with traditional three‐bag regimen in paracetamol overdose. Clin Toxicol (Phila) 2018; 56: 1128–1134.
  • 11. Isbister GK, Downes MA, McNamara K, et al. A prospective observational study of a novel 2‐phase infusion protocol for the administration of acetylcysteine in paracetamol poisoning. Clin Toxicol (Phila) 2016; 54: 120–126.
  • 12. Wong A, Isbister GK, McNulty R, et al. Efficacy of a two bag acetylcysteine regimen to treat paracetamol overdose [Abstract], 39th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT); 21–24 May 2019, Naples, Italy. Clin Toxicol (Phila) 2019; 57: 535.
  • 13. Chiew AL, Isbister GK, Kirby KA, et al. Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM‐2). Clin Toxicol (Phila) 2017; 55: 1055–1065.
  • 14. Duffull SB, Isbister GK. Predicting the requirement for N‐acetylcysteine in paracetamol poisoning from reported dose. Clin Toxicol (Phila) 2013; 51: 772–776.
  • 15. Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N‐acetylcysteine treatment after acetaminophen (paracetamol) overdose. Clin Toxicol (Phila) 1999; 37: 753–757.
  • 16. Marks DJB, Dargan PI, Archer JRH, et al. Outcomes from massive paracetamol overdose: a retrospective observational study. Br J Clin Pharmacol 2017; 83: 1263–1272.
  • 17. Cairney DG, Beckwith HK, Al‐Hourani K, et al. Plasma paracetamol concentration at hospital presentation has a dose‐dependent relationship with liver injury despite prompt treatment with intravenous acetylcysteine. Clin Toxicol (Phila) 2016; 54: 405–410.
  • 18. Hendrickson RG. What is the most appropriate dose of N‐acetylcysteine after massive acetaminophen overdose? Clin Toxicol (Phila) 2019; 57: 686–691.
  • 19. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. Clin Toxicol (Phila) 2002; 40: 3–20.
  • 20. Doyon S, Klein‐Schwartz W. Hepatotoxicity despite early administration of intravenous N‐acetylcysteine for acute acetaminophen overdose. Acad Emerg Med 2009; 16: 34–39.
  • 21. Chiew AL, Isbister GK, Page CB, et al. Modified release paracetamol overdose: a prospective observational study (ATOM‐3). Clin Toxicol (Phila) 2018; 56: 810–819.
  • 22. Graudins A, Chiew A, Chan B. Overdose with modified‐release paracetamol results in delayed and prolonged absorption of paracetamol. J Intern Med 2010; 40: 72–76.
  • 23. Salmonson H, Sjoberg G, Brogren J. The standard treatment protocol for paracetamol poisoning may be inadequate following overdose with modified release formulation: a pharmacokinetic and clinical analysis of 53 cases. Clin Toxicol (Phila) 2018; 56: 63–68.
  • 24. Anderson BJ, Holford NH, Armishaw JC, Aicken R. Predicting concentrations in children presenting with acetaminophen overdose. J Pediatr 1999; 135: 290–295.
  • 25. Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther 2000; 7: 99–114.
  • 26. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296: 87–93.
  • 27. Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity — where do we go from here? Expert Opin Drug Saf 2007; 6: 341–355.
  • 28. Kalsi SS, Dargan PI, Waring WS, Wood DM. A review of the evidence concerning hepatic glutathione depletion and susceptibility to hepatotoxicity after paracetamol overdose. Open Access Emerg Med 2011; 3: 87–96.
  • 29. Daly FF, O'Malley GF, Heard K, et al. Prospective evaluation of repeated supratherapeutic acetaminophen (paracetamol) ingestion. Ann Emerg Med 2004; 44: 393–398.
  • 30. Egan H, Isbister GK, Robinson J, et al. Retrospective evaluation of repeated supratherapeutic ingestion (RSTI) of paracetamol. Clin Toxicol (Phila) 2019; 57: 703–711.
  • 31. Acheampong P, Thomas SH. Determinants of hepatotoxicity after repeated supratherapeutic paracetamol ingestion: systematic review of reported cases. Br J Clin Pharmacol 2016; 82: 923–931.
  • 32. Wong A, Gunja N, McNulty R, Graudins A. Analysis of an 8‐hour acetylcysteine infusion protocol for repeated supratherapeutic ingestion (RSTI) of paracetamol. Clin Toxicol (Phila) 2018; 56: 199–203.
  • 33. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N‐acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319: 1557–1562.
  • 34. Cairns R, Brown JA, Wylie CE, et al. Paracetamol poisoning in Australia, 2004‐2017: an analysis of overdose frequency, overdose size, liver injury and deaths. Med J Aust 2019; 211: 218–223. https://www.mja.com.au/journal/2019/211/5/paracetamol-poisoning-related-hospital-admissions-and-deaths-australia-2004-2017
  • 35. Green TJ, Sivilotti ML, Langmann C, et al. When do the aminotransferases rise after acute acetaminophen overdose? Clin Toxicol (Phila) 2010; 48: 787–792.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Rescheduling codeine‐containing analgesics reduced codeine‐related hospital presentations

Keith Harris, Andrew Jiang, Robert Knoeckel and Katherine Z Isoardi
Med J Aust 2020; 212 (7): . || doi: 10.5694/mja2.50400
Published online: 25 November 2019

Until recently, analgesic medications containing less than 30 mg codeine per dosage unit were available over the counter in Australia.1 Codeine‐related hospital presentations placed an increasing economic burden on the Australian health care system;2 in response, the Therapeutic Goods Administration re‐scheduled all codeine‐containing products as prescription‐only medicines from 1 February 2018.3

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 Princess Alexandra Hospital, Brisbane, QLD
  • 2 University of Queensland, Brisbane, QLD



Competing interests:

No relevant disclosures.

  • 1. Mill D, Johnson JL, Cock V, et al. Counting the cost of over‐the‐counter codeine containing analgesic misuse: a retrospective review of hospital admissions over a 5 year period. Drug Alcohol Rev 2018; 37: 247–256.
  • 2. Roberts DM, Nielsen S. Changes for codeine. Aust Prescr 2018; 41: 2–3.
  • 3. Therapeutic Goods Administration. Update on the proposal for the rescheduling of codeine products [media release]. 20 Dec 2016. https://www.tga.gov.au/media-release/update-proposal-rescheduling-codeine-products (viewed July 2019).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Pagination

Subscribe to